When the World Health Organization (WHO) updated its recommendations for the human papillomavirus (HPV) vaccine in late 2022, it stated that a single-dose schedule could provide a comparable efficacy and durability of cancer protection compared to a two-dose regimen.
Since sexually transmitted HPV causes more than 95% of cervical cancer, many countries sought independent clinical research to support the WHO's revised recommendation.
Read More